SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2026

SEGMENT INFORMATION

SEGMENT INFORMATION

NOTE 7 – SEGMENT INFORMATION

a. The Company operates in Israel as a single operating segment. The Company’s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results on a consolidated basis based on net income (losses).

b. Segment information:

	Three Months Ended March 31,
(U.S. dollars in thousands)	2026		2025
Revenues from customers	$	33,750	$	10,113
Less:
Employee salaries and related expenses		6,697		5,205
Sub-contractors expense		4,441		2,689
Interest expense		-		6
Interest income		(188)		(419)
Depreciation		404		346
Other segment expenses*		1,255		6,018
Income (loss) before taxes on income		21,141		(3,732)
Taxes on income (tax benefit)		2,824		(113)
Segment net income (loss)	$	18,317	$	(3,619)

* Other expenses included in net income include raw materials, rent and utilities, and others.

c. The following table summarizes the Company’s disaggregation of revenues:

	Three Months Ended March 31,
(U.S. dollars in thousands)	2026		2025
Gaucher disease:
Pfizer (Ireland)	$	1,452	$	6,979
Fiocruz (Brazil)	$	2,454	$	3,016
Fabry disease:
Chiesi (Italy)	$	3,513	$	-
Total revenues from selling goods	$	7,419	$	9,995
Revenues from license and R&D services	$	26,331	$	118

d. Long lived assets are located in Israel.